PATENT CLAIM ANALYSIS

Application Number: 15864494
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "227100"]

Abstract:
Provided are human antibodies that specifically bind to HBV Pre-S1 domain ligand and inhibit HBV or HDV infection, antibodies binding to a set of amino acid residues that are critical for viral receptor engagement, and uses of these antibodies to prevent, or treat or diagnose HBV or HDV infection.

Claim (Index 12):
The antibody, or antigen-binding fragment thereof, of  claim 11 , wherein the light chain variable region CDR1, CDR2, and CDR3 domains are selected from the group consisting of:\n a) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 62, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 63, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 64; b) a light chain variable region CDR1 comprising amino acids having the sequence set forth in residues 1-12 of SEQ ID NO: 68, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 69, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 70; c) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 74, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 75, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 76; d) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 80, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 81, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 82; e) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 86, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 87, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 88; f) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 92, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 93, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 94; g) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 98, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 99, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 100; h) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 131, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 132, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 133; i) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 134, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 135, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 136; j) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 137, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 138, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 139; k) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 140, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 141, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 142; and l) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 143, a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 144, and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 145.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 86.0
- Lexical Diversity: 1.47222
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15766593', '12322861', '13466439', '14449478', '15302018']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7590800363110284
- 35 USC 102 Novelty (BERT): 0.5268359019691504
- Combined Prediction Score: 0.7358556228768406
- Mean Citation Score: 341.3386900000001
- Max Citation Score: 354.49304
- Similarity Product: 265.8999528285026

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test